JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640
Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).
While clinically significant ILD occurs in around 10% of patients with RA, there remains a lack of data regarding the risk of its development in patients treated with different b/tsDMARDS. To help address this, Baker, et al. estimated the incidence of ILD in patients with RA treated with different b/tsDMARDS, and compared the risk between the different agents, and adalimumab (the most commonly prescribed therapy in the dataset).